Selexipag is an oral selective IP prostacyclin receptor agonist. This study, presented during an oral session at the International Society for Heart and Lung Transplant (ISHLT) congress on April 29, 2025, provides the longest follow-up data available for any pulmonary arterial hypertension therapy, tracking 574 patients originally randomized to selexipag in the GRIPHON trial, with 330 continuing into the open-label extension for up to 10 years of treatment.
Read more at this link on the and see also our recent article here
Presenters: V. V. McLaughlin, L. Howard, J. Elwing, C. C. Fernandes, S. Gaine, N. Galie, N. Martin, R. J. Oudiz, P. Strachan, Y. Tamura, N. H. Kim.
